MODULEX
5.5.2022 15:02:06 CEST | Business Wire | Pressemeddelelse
Modulex A/S er globalt markedsledende inden for visuel kommunikation med 30 salgsenheder og flere produktionsfaciliteter rundt omkring i verden. Modulex A/S leverer wayfinding og arkitektoniske skilteløsninger samt multi-site brandimplementering og er den førende producent af systemskilte på verdensplan.
Koncernen sluttede 2021 med et EBITDA resultat på 17 mio. kr.
Mens koncernen som helhed leverede et flot resultat, er flere salgsenheder som fx Modulex Hospitality, der primært leverer skilteløsninger til internationale hotelkæder og ferieresorts, fortsat alvorligt påvirket af den globale pandemi og er først begyndt at se tegn på opsving i år. På trods af at det mange steder stadig er vanskeligt fysisk at besøge projekter og kunder, holdt de lokale kontorer verden over fast. Globalt set har Modulex Gruppen haft det bedste år i koncernens historie og har i løbet af året leveret og implementeret nogle meget store virksomhedsrebrands i både USA og Vesteuropa.
”Set i lyset af det pres, vi oplever på leveringstider og råmaterialer som aluminium, er vores resultat meget flot," siger Ketil M. Staalesen, administrerende direktør og hovedaktionær i Modulex Gruppen. "Vores produktionsteam udnyttede partnerskaber etableret gennem mange års samarbejde til at sikre, at vi kunne imødekomme vores kunders krav. Vores forretningsudviklingsstrategi fokuserede på at fremme miljøvenlige produkter som Etronit og Greenbond™, som er mindre påvirket af leveringsmæssige udfordringer."
Modulex Gruppen vil i 2022 fokusere på design-build-strategien, globale kunder, mere miljøvenlige produkter og lanceringen af den cloud-baserede projektstyringssoftware e-Modulex. Modulex har allerede indgået nye.
"2022 bliver stadig en udfordring," siger Staalesen. “Men vores solide forretningsstrategi og vores ledelsesteams evne til at kæmpe gennem de seneste to år inspirerer mig. Jeg kunne ikke være mere stolt af dem, og jeg forventer, at vi overgår vores forventninger i år."
Om Modulex Gruppen:
Modulex Gruppen, som blev grundlagt i 1963 af LEGO-koncernen og som siden 2009 har været ejet af ledelsen samt andre eksterne investorer, er global markedsleder inden for visuel kommunikation og brandimplementering. Med rod i dansk designekscellence og et modulært skiltekoncept har Modulex udviklet sin platform yderligere med design, wayfinding, brugerdefinerede løsninger og brandimplementeringer. Fabrikken i Billund, som er ISO 9001-certificeret, lancerede i 2019 en mere miljøvenlig produktlinje. Modulex Billund blev tildelt Green Network-diplomet for niende år i træk. Modulex Gruppen har fem fabrikker globalt. Koncernen er repræsenteret i over 300 byer på tværs af 45 lande, hvilket giver Modulex Gruppen den nødvendige rækkevidde og evne til at leve op til sit løfte om global vision, lokal rækkevidde og én virksomhed.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220505005139/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum